Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
India · Delayed Price · Currency is INR | Market Cap | 4.06T |
| Revenue (ttm) | 549.64B |
| Net Income (ttm) | 104.50B |
| Shares Out | 2.40B |
| EPS (ttm) | 43.55 |
| PE Ratio | 38.84 |
| Forward PE | 33.82 |
| Dividend | 16.00 (0.95%) |
| Ex-Dividend Date | Jul 7, 2025 |
| Volume | 1,512,864 |
| Average Volume | 1,789,549 |
| Open | 1,694.00 |
| Previous Close | 1,685.90 |
| Day's Range | 1,683.10 - 1,710.00 |
| 52-Week Range | 1,548.00 - 1,910.00 |
| Beta | 0.27 |
| RSI | 55.98 |
| Earnings Date | Nov 5, 2025 |
About NSE:SUNPHARMA
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, urology, dermatology, respira... [Read more]
Financial Performance
In 2024, NSE:SUNPHARMA's revenue was 525.78 billion, an increase of 8.42% compared to the previous year's 484.97 billion. Earnings were 109.29 billion, an increase of 14.12%.
Financial StatementsNews
Sun Pharma share: Nomura upgrades to buy, expects 16% upside on strong branded generics growth and favourable risk-reward
Nomura has upgraded Sun Pharma to a buy call with a target price of ₹1,960 per share, implying a potential...
Sun Pharmaceuticals Industries Ltd (BOM:524715) Q2 2026 Earnings Call Highlights: Strong Sales ...
Sun Pharmaceuticals Industries Ltd (BOM:524715) Q2 2026 Earnings Call Highlights: Strong Sales Growth Amidst US Market Challenges
Q2 2026 Sun Pharmaceutical Industries Ltd Earnings Call Transcript
Q2 2026 Sun Pharmaceutical Industries Ltd Earnings Call Transcript
Sun Pharmaceuticals Industries Ltd (NSE:SUNPHARMA) Q2 2026 Earnings Report Preview: What To Expect
Sun Pharmaceuticals Industries Ltd (NSE:SUNPHARMA) Q2 2026 Earnings Report Preview: What To Expect
Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout
MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. ("Urica" or the "Company"), a Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress") subsidiary, today announced that Crystalys Therapeut...
Stocks to Watch Today, October 9: HFCL, Coal India, Prestige Estates, GR Infra, Lupin, Senco Gold, Saatvik Green, Adani Power, Sun Pharma in focus
Indian equities are set for a stock-specific session on Thursday, October 9, 2025, as several companies announced project wins, business...
Sun Pharma shares rally nearly 3% as Citi reiterates ‘Buy’ rating, says pricing overhangs now resolved after Pfizer deal
Sun Pharmaceutical Industries Ltd. shares surged nearly 3% on strong investor sentiment after Citi reiterated its buy rating for the stock, setting a target price of ₹2,180 per share. The brokerage hi...
[Brokerage Calls] Stocks to watch on October 1: Ultratech Cement, Muthoot Finance, Manappuram Finance, Amber, Syrma SGS, Sun Pharma and more
Brokerages have released a fresh set of recommendations across cement, gold financiers, consumer, pharma, and technology sectors. The tone remains largely positive with selective neutral calls as mark...
Citi bullish on Sun Pharma shares, says MFN and pricing overhangs now resolved after Pfizer deal
Citi has reiterated its buy rating on Sun Pharmaceutical Industries with a target price of ₹2,180 per share, noting that key overhangs related to trade and pricing risks have eased significantly. The ...
Stock Market Live Updates Today, October 1: Adani Enterprises, Power Grid, Adani Green, L&T Technology in focus
Welcome to Business Upturn’s live coverage of the Indian stock market on October 1 2025. The trading session is expected to remain stock-specific as several companies announced key developments. In fo...
Top stocks to watch today, October 1: Adani Enterprises, Sun Pharma, L&T Technology, Adani Green and more
As the market opens on October 1, several major companies are in focus following fresh announcements, regulatory approvals, and business developments. Here are the top stocks investors should track to...
Trump's 100% tariffs on branded drugs: Indian generics spared but poses risks for pharma sector – Explained
US President Trump announced a 100% tariff on imported branded and patented pharmaceuticals starting October 2025, aiming to boost domestic manufacturing. Indian generic drug makers are largely unaffe...
Not a med emergency: Generic pharma cos spared from harm
Trump's new 100% pharma levy primarily targets branded and patented medicines, potentially impacting Sun Pharma and Biocon's US sales. While most Indian generic firms anticipate business as usual, som...
Trump’s 100% tariffs on branded drugs: Which Indian pharma stocks are most vulnerable? Experts weigh in
Donald Trump's tariff move impacts Indian pharma stocks. Companies like Sun Pharma, Cipla, and Dr. Reddy's face potential declines. US represents a major market for Indian exports.
Trump’s 100% tariffs on pharma: Sun Pharma, Biocon, Cipla & other pharmaceutical stocks tank; jitters on D-Street
Pharmaceutical stocks, particularly Indian firms, plummeted following President Trump's announcement of 100% tariffs on imported branded medicines to the US. Companies like Sun Pharma, Biocon, and Zyd...
Sun Pharma falls nearly 3% as Trump’s 100% tariff on pharma imports spooks sector
Shares of Sun Pharmaceutical Industries Ltd dropped 2.61% to ₹1,585 in Friday’s early trade, September 26, after U.S. President Donald Trump announced a 100% tariff on imports of branded and patented ...
Gland Pharma down 4%, Sun Pharma slips 2.6%, Dr Reddy’s down 2%, Zydus nearly 3%, Aurobindo down 2% as Trump’s 100% pharma tariff jolts sector
Indian pharmaceutical stocks came under heavy selling pressure on Friday, September 26, after U.S. President Donald Trump announced a 100% tariff on imports of branded and patented pharmaceutical drug...
Top stocks to watch today, September 26: Tata Motors, L&T, TVS Motor, Polycab India, Sun Pharma and more
Indian equities are set for another action-packed session on Friday, September 26, with several major corporate developments and global cues influencing investor sentiment. From auto giants to pharma ...
Indian pharma stocks in focus as Trump announces 100% tariff on branded drugs
Indian pharma shares such as Sun Pharma, Lupin, Dr. Reddy’s, Cipla, and Aurobindo Pharma are in focus after Donald Trump announced a 100% tariff on imported branded drugs, effective October 1, unless ...
Morgan Stanley reiterates overweight on Sun Pharma with Rs 1,948 target price, says well placed in chronic portfolio and specialty expansion
Morgan Stanley has reiterated its overweight rating on Sun Pharma with a target price of ₹1,948, citing its strong domestic positioning and expanding specialty portfolio. The brokerage expects the com...
Jefferies reiterates buy on Sun Pharma with Rs 2,070 target, says new launches and India focus to sustain growth
Jefferies has maintained its buy rating on Sun Pharma with a target price of ₹2,070 after a recent management meeting, highlighting the company’s strategy of balancing growth in India with expansion i...
Nifty top gainers today, September 18: Eternal, HDFC Life, Sun Pharma, Cipla, Infosys and more
Indian equity benchmarks closed higher on September 18. The BSE Sensex rose 320.25 points, or 0.39%, to end at 83,013.96, while the NSE Nifty 50 gained 93.35 points, or 0.37%, to finish at 25,423.60. ...
ICICI Bank, PNB Housing, Sun Pharma, D-Mart, Shriram Finance among top picks with 15–35% upside, say brokerages
Brokerage notes released today pointed out several stocks that could deliver more than 15% potential upside from current levels. The key highlights are presented in the table below: Stock Brokerage Ca...
Sun Pharma share: Citi maintains buy, sees 35% upside on innovation revenue growth and global expansion
Sun Pharma stock: Citi target at ₹2,180 implies 34.6% gain, driven by Ilumya approval and US expansion
Top stocks to watch today, September 10: Bajaj Auto, Eicher Motors, Yes Bank, Sun Pharma and more
Indian equities are expected to see stock-specific action today as several companies announced key developments and updates. Here are the major stocks to watch on Tuesday, September 10: Bajaj Auto: Th...